参考文献/References:
[1] 中华医学会神经病学分会.中华医学会神经病学分会睡眠障碍学组,解放军医学科学技术委员会神经内科专业委员会睡眠障碍.中国发作性睡病诊断与治疗指南[J].中华神经科杂志,2015,48(6):1006-7876.
[2] Tafti M,Hor H,Dauvilliers Y,et al.DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe[J].Sleep,2014,37(1):19-U228.
[3] Yamasaki M,Miyagawa T,Toyoda H,et al.Evaluation of polygenic risks for narcolepsy and essential hypersomnia[J].J Hum Genet,2016,61(10):873-878.
[4] Ollila HM,Ravel JM,Han F,et al.HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy[J].Am J Hum Genet,2015,96(1):136-146.
[5] Peyron C,Bernard-Valnet R,Yshii L,et al.CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice[J].J Sleep Res,2016,25(1, SI):82-83.
[6] Hartmann FJ,Bernard-Valnet R,Queriault C,et al.High-dimensional single-cell analysis reveals the immune signature of narcolepsy[J].Journal of Experimental Medicine,2016,213(12):2621-2633.
[7] Tesoriero C,Codita A,Zhang MD,et al.H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice[J].Proc Natl Acad Sci U S A,2016,113(3):E368-E377.
[8] Saariaho AH,Vuorela A,Freitag TL,et al.Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus[J].J Autoimmun,2015,63(3):68-75.
[9] Veatch OJ,Keenan BR,Gehrman PR,et al.Pleiotropic genetic effects influencing sleep and neurological disorders[J].Lancet Neurol,2017,16(2):158-170.
[10] Wing YK,Chen L,Lam SP,et al.Familial aggregation of narcolepsy[J].Sleep Med,2011,12(10):947-951.
[11] Peraita-Adrados R,Del RR,Vela-Bueno A.Environmental factors in the development of narcolepsy with cataplexy.A case-control study[J].Rev Neurol,2015,60(12):529-534.
[12] Liblau RS,Vassalli A,Seifinejad A,et al.Hypocretin(orexin)biology and the pathophysiology of narcolepsy with cataplexy[J].Lancet Neurol,2015,14(3):318-328.
[13] Burgess CR,Scammell TE.Narcolepsy: neural mechanisms of sleepiness and cataplexy[J].Journal of Neuroscience,2012,32(36):12305-12311.
[14] Burgess CR,Oishi Y,Mochizuki T,et al.Amygdala lesions reduce cataplexy in orexin knock-out mice[J].J Neurosci,2013,33(23):5612-5632.
[15] Reiter J,Katz E,Scammell TE,et al.Usefulness of a nocturnal SOREMP for diagnosing narcolepsy with cataplexy in a pediatric population[J].Sleep,2015,38(6):859-865.
[16] Carter LP,Acebo C,Kim A.Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review[J].Postgrad Med,2014,126(3):216-224.
[17] Dias CF,Barreto M,Clemente V,et al.Narcolepsy in pediatric age-Experience of a tertiary pediatric hospital[J].Sleep SciDOI:10.1016/j.slsci,2014,7(1):53-58.
[18] Scammell TE. Narcolepsy[J].N Engl J Med,2015,373(27):2654-2662.
[19] Maski K,Owens JA.Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management[J].Lancet Neurol,2016,15(11):1170-1181.
[20] Goldbart A,Peppard P,Finn L,et al.Narcolepsy and predictors of positive MSLTs in the Wisconsin sleep cohort[J].Sleep,2014,37(6):1043-1051.
[21] Raizen DM,Wu MN.Genome-Wide association studies of sleep disorders[J].Chest,2011,139(2):446-452.
[22] Cingoz S,Agilkaya S,Oztura I,et al.Identification of the variations in the CPT1B and CHKB genes along with the HLA-DQB1*06:02 allele in Turkish narcolepsy patients and healthy persons[J].Genet Test Mol BiomarkersDOI:10.1089/gtmb,2013,18(4):261-268.
[23] Vrana M,Siffnerova V,Pecherkova P,et al.Distribution of HLA-DQB1 in czech patients with central hypersomnias[J].Arch Immunol Ther Exp(Warsz),2016,64(1):S89-S98.
[24] Lopez R,Barateau L,Evangelista E,et al.Temporal changes in the cerebrospinal fluid level of hypocretin-1 and histamine in narcolepsy[J].J Sleep Res,2016,25(1, SI):82.
[25] Dauvilliers Y,Beziat S,Pesenti C,et al.Measurement of narcolepsy symptoms:The Narcolepsy Severity Scale[J].Neurology,2017,88(14):1358-1365.
[26] Murali H,Kotagal S.Off-label treatment of severe childhood narcolepsy-cataplexy with Sodium oxybate[J].Sleep,2006,29(8):1025-1029.
[27] Buskova J,Vaneckova M,Sonka K,et al.Reduced hypothalamic gray matter in narcolepsy with cataplexy[J].Neuro Endocrinol Lett,2006,27(6):769-772.
[28] Weng HH,Chen CF,Tsai YH,et al.Gray matter atrophy in narcolepsy: An activation likelihood estimation meta-analysis[J].Neurosci Biobehav Rev,2015,59(2):53-63.
[29] Menzler K,Belke M,Unger MM,et al.DTI reveals hypothalamic and brainstem white matter lesions in patients with idiopathic narcolepsy[J].Sleep Med,2012,13(6):736-742.
[30] Mignot EJ.A practical guide to the therapy of narcolepsy and hypersomnia syndromes[J].Neurotherapeutics,2012,9(4):739-752.
[31] Com G,Einen MA,Jambhekar S.Narcolepsy with cataplexy: diagnostic challenge in children[J].Clin Pediatr(Phila),2015,54(1):5-14.
[32] Malhotra S,Kushida C.Primary hypersomnias of central origin[J].Continuum(Minneap Minn),2013,19(1 Sleep Disorders):67-85.
[33] Busardo FP,Kyriakou C,Napoletano S,et al.Clinical applications of Sodium oxybate(GHB): from narcolepsy to alcohol withdrawal syndrome[J].Eur Rev Med Pharmacol Sci,2015,19(23):4654-4663.
[34] Bogan RK,Roth T,Schwartz JA.Time to response with Sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy[J].Journal of Clinical Sleep Medicine,2015,11(4):427-432.
[35] Aran A,Einen M,Lin L,et al.Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children[J].Sleep,2010,33(11):1457-1464.
[36] Kallweit U,Bassetti CL.Pharmacological management of narcolepsy with and without cataplexy[J].Expert Opin Pharmacother,2017,18(8):809-817.
[37] Herr n-Arita LA.Garc a-Garc a F.current and emerging options for the drug treatment of narcolepsy[J].Drugs,2013,73(16):1771-1781.
[38] Philip P,Chaufton C,Taillard J,et al.Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial[J].Sleep,2014,37(3):483-487.
[39] Bayram AK,Per H,Ismailogullari SA,et al.Efficiency of a combination of pharmacological treatment and nondrug interventions in childhood narcolepsy[J].Neuropediatrics,2016,47(6):380-387.
[40] Dauvilliers Y,Bassetti C,Lammers GJ,et al.Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial[J].Lancet Neurol,2013,12(11):1068-1075.
[41] Liu M,Blanco-Centurion C,Konadhode RR,et al.Orexin gene transfer into the amygdala suppresses both spontaneous and emotion-induced cataplexy in orexin-knockout mice[J].European Journal of Neuroscience,2016,43(5):681-688.